Not FDA-approved · Phase I/II completed for sarcoidosis neuropathy and diabetic neuropathy · Orphan drug designation · Research chemical
Human evidence
Moderate — Phase I/II data confirming neuropathic pain reduction and structural nerve fiber density increase in humans
Preclinical evidence
Moderate — IRR mechanism, anti-inflammatory, and neuroprotective effects confirmed
EDUCATIONAL TOOL — NOT MEDICAL ADVICE
What is ARA-290?
ARA-290 was engineered from erythropoietin (EPO) to isolate its tissue-protective functions from its erythropoietic (red blood cell-producing) functions. EPO receptors exist throughout the body — in neurons, heart, kidneys, immune cells — where EPO activation promotes survival, reduces inflammation, and supports repair. ARA-290 targets the 'innate repair receptor' (IRR), a heteromeric EPOR/βcR complex expressed in non-hematopoietic tissue, without activating the homodimeric EPOR that drives red blood cell production. All the protection, none of the blood-thickening risk.
The human evidence is concentrated in neuropathic pain. A Phase II trial in sarcoidosis patients with small fiber neuropathy showed ARA-290 significantly reduced pain scores — and crucially, increased intraepidermal nerve fiber density on skin biopsy. This is direct evidence of structural nerve regeneration in humans, not just symptomatic relief. A diabetic neuropathy Phase II trial showed improved pain scores alongside improved HbA1c — suggesting concurrent metabolic benefit.
For biohackers, ARA-290 occupies a specific niche: neuropathic pain management, nerve regeneration support, anti-inflammatory effects for chronic inflammatory conditions, and potentially metabolic improvement via beta cell protection. It's rarely discussed in mainstream biohacker spaces but has a devoted community among people who have researched EPO's tissue-protective biology or who are dealing with chronic neuropathic conditions.
How it works
Innate Repair Receptor (IRR) Activation
ARA-290 binds the IRR — a heteromeric complex of one EPO receptor subunit and one beta-common receptor (βcR) subunit — expressed in neurons, cardiomyocytes, renal cells, beta cells, and immune cells. Activation drives JAK2/STAT5 and PI3K/Akt pro-survival signaling. Critically, this receptor configuration does not drive erythropoiesis — that requires the homodimeric EPOR that ARA-290 has minimal affinity for.
Neuroprotection and Structural Nerve Regeneration
In peripheral nerves: promotes Schwann cell survival, stimulates axonal regeneration, reduces neuroinflammation. The Phase II increase in intraepidermal nerve fiber density confirms structural regeneration in humans — small fibers lost due to sarcoidosis-driven inflammation regrew during ARA-290 treatment. This is the strongest and most clinically meaningful finding from the ARA-290 evidence base.
IRR expression on pancreatic beta cells: ARA-290 protects them from inflammatory damage and may improve insulin sensitivity. The HbA1c improvement in the diabetic neuropathy trial suggests functional metabolic benefit alongside the neuroprotective effects — though whether this is direct beta cell protection or secondary to reduced inflammation requires further study.
What the research shows
STUDYMolecular Medicine · 2014
ARA-290 for small fiber neuropathy in sarcoidosis — Phase II RCT
Brines M et al.
39 patients with sarcoidosis-related small fiber neuropathy. ARA-290 SC for 28 days. Significant pain reduction vs. placebo. Intraepidermal nerve fiber density increased on skin biopsy — structural nerve regeneration confirmed in humans. Strongest ARA-290 evidence.
48 diabetic neuropathy patients. Significant pain reduction + improved HbA1c in ARA-290 group vs. placebo. Supports both neuroprotective and metabolic mechanisms simultaneously.
✓IRR activation without erythropoiesis — mechanistically confirmed, no hematocrit increase in trials
✓Intraepidermal nerve fiber density increase in Phase II — structural human nerve regeneration
✓Neuropathic pain reduction in Phase II RCTs — sarcoidosis and diabetic neuropathy
✓Anti-inflammatory macrophage polarization and cytokine reduction
?UNCERTAIN
?Long-term nerve regeneration maintenance after stopping
?Anti-inflammatory effects at biohacker doses vs. trial doses
?Metabolic benefits in non-diabetic, non-neuropathic users
?Optimal duration and frequency for nerve regeneration
What the community reports
—Neuropathic pain reduction — most important reported effect; users with chronic nerve pain report significant relief consistent with the Phase II data
—Gradual improvement over weeks — not immediate; nerve regeneration takes time; most users report peak benefit at 3–4 weeks into a course
—Anti-inflammatory benefits beyond nerve pain in some users — reduced systemic inflammation markers
—Metabolic improvements (glucose management) in insulin-resistant users
—Very clean safety profile — no erythropoietic effects; well-tolerated in trials; community reports match
Common misconceptions
"ARA-290 thickens the blood like EPO."
REALITY
ARA-290 targets IRR, not the homodimeric EPOR that drives erythropoiesis. No increase in red blood cells, hematocrit, or thrombosis risk observed in trials. The risk profile is completely different from conventional EPO — this was the entire design intent.
"ARA-290 is a performance enhancer like EPO."
REALITY
EPO increases endurance via more red blood cells and oxygen delivery. ARA-290 doesn't increase red blood cells — it has tissue-protective, anti-inflammatory, and neuroprotective effects. Not a performance compound in the EPO sense. Different receptor, different biological outcome.
NEUROPROTECTIVE PEPTIDE COMPARISON
ARA-290: EPO-derived, IRR activation, nerve regeneration + anti-inflammatory. Best for neuropathic pain and nerve repair. BPC-157: broad tissue repair, GI + musculoskeletal + neural via NO/growth factors. Cerebrolysin: BDNF/NGF mimicry, 150+ clinical trials, CNS-focused neuroprotection. LL-37: antimicrobial + anti-inflammatory via different immune pathways.
RECONSTITUTION CALCULATOR
EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN
AI COACH PREVIEW
I have diabetic neuropathy. How should I structure an ARA-290 protocol and what should I track?
The Phase II data gives a good starting framework for protocol design — let me walk through it and adapt it for ongoing tracking. The clinical protocol from the Brines/Dahan trials: 4 mcg/kg SC daily for 28 days. For an 80 kg person, that's approximately 320 mcg per day. This is the most evidence-based approach — it maps directly to what produced both pain reduction and improved HbA1c in the diabetic neuropathy trial. Timeline of expectations: Nerve pain reduction typically begins 1–2 weeks in, with peak benefit around week 3–4 of the course. Nerve regeneration (structural changes like nerve fiber density) takes longer — weeks to months of sustained signaling. Don't evaluate this compound by day 5. What to track for neuropathic pain: Establish a baseline before injection #1. Use a consistent daily pain scale (0-10) at the same time of day. Rate burning, tingling, and numbness separately — these often change at different rates. Track functional capacity: what can you do now that was difficult before? Weekly: fasting glucose and postprandial glucose if you're monitoring the metabolic component — the HbA1c improvement in the trial suggests real beta cell/insulin sensitivity benefit. After the 28-day course: repeat your baseline assessments. If improvement is meaningful, plan a second course 4-6 weeks later. Repeat courses 2–4 times per year is the community standard. Is your neuropathy primarily pain, loss of sensation, or both? That affects which symptoms to prioritize in your tracking.
CONTINUE IN THE APP
Open PepperLedger to track your ARA-290 protocol →
Free to join. No credit card. Ask the Coach about your neuropathy management protocol once you're in.
Free to join · No credit card · 23-day Pro trial included